BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OncoImmune Ltd Names Mike Luecke First CEO


10/19/2005 5:10:14 PM

COLUMBUS, Ohio--(BUSINESS WIRE)--March 2, 2004--After a nationwide search, OncoImmune Ltd, developer of therapeutics for diseases that include multiple sclerosis and cancer, announced today that it has named Michael C. Luecke Chief Executive Officer.

Luecke's experience includes more than 25 years of leading both small biotechnology and major pharmaceutical companies. He was CEO of two successful San Diego biotechnology startups - Clonetics and Angstrom. His knowledge of immunotherapeutics, oncology and autoimmune diseases is complemented by a strong track record in corporate partnering and extensive contacts in the investment community.

"We are enormously pleased that Mr. Luecke has joined our team," said Dr. Yang Liu, chairman and co-founder of OncoImmune. "His extensive expertise in both biotechnology companies and large pharmaceutical companies makes him eminently qualified to lead OncoImmune. This addition to our team will accelerate corporate growth, clinical development and strategic alliances for our emerging product pipeline.

Located in the Business Technology Center, three-year-old OncoImmune has received numerous NIH grants and support through Ohio's Technology Action Fund. The Company has licensed a strong portfolio of proprietary technologies based on discoveries made by eminent scientists at Ohio State University, the University of Michigan and Washington University in St. Louis.

"This is a very exciting time to join OncoImmune," Luecke commented. "We are poised to make a rapid transition from a research-based startup with great science into a drug development biopharmaceutical company with large market potential and multiple products."

Luecke also was formerly the west coast partner for the Mattson Jack Group, a leading pharmaceutical consulting firm. Previously, he was Director of Business Development at Bristol-Myers in New York, and earlier was Director of Corporate Strategy Development at SmithKline in Philadelphia and a manager with Novartis. He holds an MBA from Northwestern and BS from Notre Dame.

Contacts

OncoImmune Dr. Li-Hui Xu, 614-340-1686



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES